Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) is a highly malignant type of tumor that is insensitive to cytotoxic chemotherapy and often develops drug resistance. Nevadensin, a bioflavonoid, exhibits anti-cancer properties in some cancers. However, the precise underlying mechanism of nevadensin agains...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Hewen, Zou, Ying, Wang, Xiaoxue, Wang, Guoli, Gao, Yijia, Yi, Fan, Xu, junqing, Yin, Yancun, Li, Defang, Li, Minjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224888/
https://www.ncbi.nlm.nih.gov/pubmed/37243813
http://dx.doi.org/10.1007/s12672-023-00699-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224888/
https://www.ncbi.nlm.nih.gov/pubmed/37243813
http://dx.doi.org/10.1007/s12672-023-00699-y

Ejemplares similares